(1/10) Very pleased to announce our newest publication is now online at Molecular Cancer Research! @MarkARubin1 @MCR_AACR @AACR https://t.co/5dg3FxkusR

In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science https://t.co/WOGllHwEfQ

Loss of Pi5P4Ka slows the progression of Pten mutant basal cell model of prostate cancer. @JoTriscott; Marika Lehner; @AndrejBenjak; Matthias Reist; BrookeM Emerling; Charlotte https://t.co/Efvo7vqOP0; @Simone de Brot; @MarkARubin1

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 https://t.co/dyTV0eN9zy The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in

(10/10)... and final thanks to the community of editors, reviewers, and researchers around the world who are working hard to make a difference for cancer patients🤗

(9/10) Massive thank you to all the coauthors: Marika Lehner, @AndrejBenjak, Matthias Reist, @BrookeEmerling, Charlotte Ng, simone de Brot….. and much gratitude for the support from @snsf_ch, @DBMR_Unibe, Fondation Johanna Dürmüller Bol.. And anyone we missed!

(8/10) This publication is a mere snapshot of the massive amount of work that went into this research. Not just a mountain, but a >8000m Everest of effort from a great team of people.

(7/10) If you don't care about PI5P4Kα but love GEMMs, you might be interested in the scRNASeq profiling we conducted on selected Cre activated cells from the commonly used PB-Cre and Ck5-Cre GEMM prostate models (see Fig. 3).

(6/10) We show data from our prostate models that links loss of PI5P4Kα to changes in metabolic pathways, including alterations in fatty acid metabolism.

(5/10) In our new work, we found that loss of PI5P4Kα in CK5+ basal cells did not impact healthy tissue histopathology; however, loss of PI5P4Kα slowed the progression of an exceptionally aggressive model of homozygous PTEN deleted prostate cancer.

(4/10) During this project we noticed cell-type specific expression of PI5P4Kα and launched a multi-year development of a new inducible basal cell-specific GEMM.

(3/10) This is a continuation of our work published in 2023 nominating PI5P4Kα as a promising target in prostate cancer stress metabolism.

(2/10) Here we observe an enrichment for PI5P4Kα in the basal epithelium and demonstrate that loss of PI5P4Kα slows the progression of a PTEN mutant model of prostate cancer.

Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht https://t.co/TeFVVo6c9E

Rare histologic transformation of a CTNNB1 (β-catenin) mutated #prostatecancer. The challenge of treatment selected lineage plasticity @PCFnews @DBMR_UniBe https://t.co/4JC5P15dci

A moderate increase in RagC GTPase signaling drives parenchymal damage, attracting myeloid cells that worsen damage in a 2-step pro-aging vicious cycle. https://t.co/3a3JRN6emN

So exciting to see PI5P in the spotlight! Congrats to the entire team! 🥳

cancer cell-intrinsic loss of Pip4k2c promotes melanoma cell metastasis by co-opting an insulin-rich liver milieu via activation of the PI3K/AKT pathway ⁦@NatureCancer⁩ ⁦@BizarMd⁩

🏆 It was such a fantastic evening last night as I received the #PfizerResearchPrize2024 in the field of Oncology for our paper published in @ScienceAdvances🇨🇭 Big thank you to all of the coauthors, especially to @MarkARubin1 and @BrookeEmerling 🤗 @pfizer @DBMR_UniBe

Grand challenge of moving cancer whole-genome sequencing into the clinic. Comment on the largest whole-genome sequencing study- a myriad of actionable alterations and logistical,technical and economic challenges #precisionmedicine @NatureMedicine